Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C91073
http://purl.obolibrary.org/obo/NCIT_C91073
|
|---|---|
| Preferred Name | Ascrinvacumab |
| Definitions |
A fully human, IgG2 monoclonal antibody directed against activin-like receptor kinase 1 (ALK-1) with potential antineoplastic activity. Ascrinvacumab binds to and neutralizes ALK-1. This may disrupt tumor endothelial cell function and inhibit tumor angiogenesis, eventually leading to an inhibition of tumor cell proliferation. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human, IgG2 monoclonal antibody directed against activin-like receptor kinase 1 (ALK-1) with potential antineoplastic activity. Ascrinvacumab binds to and neutralizes ALK-1. This may disrupt tumor endothelial cell function and inhibit tumor angiogenesis, eventually leading to an inhibition of tumor cell proliferation. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration. |
|---|---|
| label | Ascrinvacumab
|
| prefLabel | Ascrinvacumab
|
| in_subset |
See more
See less
|
| Preferred_Name | Ascrinvacumab
|
| Is_Value_For_GDC_Property | |
| Display_Name | Ascrinvacumab
|
| Maps_To | Ascrinvacumab
|
| PDQ_Open_Trial_Search_ID | 580797
|
| Has_Target | |
| UMLS_CUI | C2984015
|
| FDA_UNII_Code | 716FQ5REVO
|
| prefixIRI | NCIT:C91073
|
| NCI_Drug_Dictionary_ID | 580797
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C91073
|
| type | |
| PDQ_Closed_Trial_Search_ID | 580797
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| CAS_Registry | 1463459-96-2
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |